Ozette, a Seattle, Washington-based life sciences startup, today announced it has raised $6 million in seed funding from Madrona Venture Group and the Allen Institute for AI (AI2). A collaboration between AI2 and the Fred Hutchinson Cancer Research Center, Ozette says it will use the seed funding, which brings its total raised to $12 million, to accelerate breakthroughs in disease-tracking.
The Ozette team has created an AI platform — its “Immune Monitoring Platform” — that can analyze massive combinations of proteins being created by individual cells. By automating the analysis, the platform can discover cells with unique and important protein profiles as it relates to disease and healthcare treatments. The initial focus is on cancer patients.